Mara Goldstein
Stock Analyst
(4.10)
# 2,334
Out of 4,648 analysts
73
Total ratings
46.67%
Success rate
15.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Buy | $26 → $32 | $17.68 | +81.00% | 2 | Jan 31, 2024 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $15.92 | +163.80% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $21.54 | +132.18% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $19.26 | +133.64% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $76.17 | +1.09% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $2.85 | +146.05% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $2.54 | +214.39% | 5 | Nov 20, 2023 | |
| LPTX Leap Therapeutics | Maintains: Buy | $20 → $12 | $3.72 | +222.58% | 5 | Nov 20, 2023 | |
| IOVA Iovance Biotherapeutics | Reiterates: Buy | $30 | $11.41 | +163.04% | 4 | Sep 15, 2023 | |
| VSTM Verastem | Reiterates: Buy | $36 | $3.91 | +820.72% | 5 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6 | $1.39 | +331.50% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $8.88 | -60.59% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.30 | +3,849.97% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $1.88 | +963.83% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $101.23 | +28.42% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $1.00 | +101.01% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $3.37 | +256.61% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.81 | +1,007.69% | 3 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $51.90 | -61.46% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $7.50 | +540.43% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $25.59 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $5.99 | +133.72% | 1 | Oct 12, 2017 |
Kura Oncology
Jan 31, 2024
Maintains: Buy
Price Target: $26 → $32
Current: $17.68
Upside: +81.00%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $15.92
Upside: +163.80%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $21.54
Upside: +132.18%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $19.26
Upside: +133.64%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $76.17
Upside: +1.09%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $2.85
Upside: +146.05%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $2.54
Upside: +214.39%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20 → $12
Current: $3.72
Upside: +222.58%
Iovance Biotherapeutics
Sep 15, 2023
Reiterates: Buy
Price Target: $30
Current: $11.41
Upside: +163.04%
Verastem
Aug 29, 2023
Reiterates: Buy
Price Target: $36
Current: $3.91
Upside: +820.72%
Aug 7, 2023
Reiterates: Neutral
Price Target: $6
Current: $1.39
Upside: +331.50%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $8.88
Upside: -60.59%
Apr 24, 2023
Reiterates: Buy
Price Target: $12
Current: $0.30
Upside: +3,849.97%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $1.88
Upside: +963.83%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $101.23
Upside: +28.42%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $1.00
Upside: +101.01%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $3.37
Upside: +256.61%
Nov 9, 2022
Upgrades: Buy
Price Target: $9
Current: $0.81
Upside: +1,007.69%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $51.90
Upside: -61.46%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $7.50
Upside: +540.43%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $25.59
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $5.99
Upside: +133.72%